Share on LinkedInShare on LinkedIn

ARTICLE · 29 MAY 2023

Steve Moore Comments On US V. Gilead Sciences Inc.

Withers LLP
Withers LLP
Contributor
Withers LLP

Withers LLP

Withers is an international law firm focused on the personal, business and philanthropic interests...

View firm profile
Explore more from Withers LLP

On May 9, 2023, a Delaware federal jury ruled in favor of Gilead in a first-of-its-kind lawsuit filed by the United States. Filed in 2019, the US Health and Human Services Department...

United StatesIntellectual Property

On May 9, 2023, a Delaware federal jury ruled in favor of Gilead in a first-of-its-kind lawsuit filed by the United States. Filed in 2019, the US Health and Human Services Department sued the biopharmaceutical company in assertion of the government's patent rights. The federal government alleged that Gilead's drugs Truvada and Descovy infringed upon patents for pre-exposure prophylaxis (PrEP), a drug regimen developed decades earlier by the Centers for Disease Control and Prevention (CDC) as a means of preventing HIV infections, to the tune of billions of dollars. The US asserted it had received no royalties and was seeking $1 billion from Gilead. Intellectual Property partner Steve Moore told Bloomberg Law that the lawsuit was "very novel and disconcerting to the industry," adding "if I was in-house again I'd be pretty worried about, 'Should we continue to keep working with the government?'" While the outcome was favorable to Gilead, the filing itself no doubt struck

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from